Matteo Rosellini

9PUBLICATIONS
44CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Francesco Massari, Matteo Rosellini, Bohuslav Melichar

|Oct 16, 2024
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.

Samuele Compagno, Chiara Casadio, Linda Galvani

|Nov 16, 2022
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.

Elisa Andrini, Alessandro Di Federico, Monia Sisi

|Sep 09, 2022
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study.

Alessandro Rizzo, Veronica Mollica, Andrea Marchetti

|Aug 25, 2022
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis.

Veronica Mollica, Francesco Massari, Elisa Andrini

|Feb 25, 2022
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?

Andrea Marchetti, Matteo Rosellini, Giacomo Nuvola

Pageof 2

Frequent Collaborators

7 joint publications

Francesco Massari

5 joint publications

Andrea Marchetti

3 joint publications

Alessandro Rizzo

2 joint publications

Alessia Cimadamore